QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic ...

Boehringer Ingelheim, one of the world's leading research-oriented pharmaceutical companies, announced that an important investment in the future by opening a new Angelika Amon Research Building on ...

Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost ... Boehringer’s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the ...

Image credit: Boehringer Ingelheim. Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The ...